Acute Ischemic Stroke, Thrombocytopenia
Conditions
Brief summary
The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.
Detailed description
Antiplatelet therapy is widely used in non-cardiogenic AIS patients for secondary prevention. However, it may also increase the risk of bleeding complications, especially in patients with thrombocytopenia. The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.
Interventions
DRUGaspirin, clopidogrel, cilostazol, and dipyridamole
Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years old * Acute ischemic stroke or transient ischemic attack with onset \< 7 days * The last blood routine test before enrollment indicates platelet count \< 100 x 10\^9 and \> 30 x 10\^9
Exclusion criteria
* Chronic renal dysfunction (GFR \< 30ml/min) or severe hepatic injury * Indications for anticoagulation therapy, e.g. atrial fibrillation * Myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past * Have or plan to receive CEA or CAS in the following 3 months * Life expectancy less than 1 year * Plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding * Pregnant or lactating women * Individuals identified by researchers as unsuitable for participation in the study due to other reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 90-day Composite events | 90 days | Composite events including ischemic stroke, hemorrhagic stroke, myocardial infarction, major extracranial hemorrhage, and vascular death within 90 days after enrollment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 90-day hemorrhagic stroke | 90 days | Hemorrhagic stroke within 90 days after enrollment |
| 90-day myocardial infarction | 90 days | Myocardial infarction within 90 days after enrollment |
| 90-day major extracranial hemorrhage | 90 days | Major extracranial hemorrhage within 90 days after enrollment |
| 90-day ischemic stroke | 90 days | Ischemic stroke within 90 days after enrollment |
| 90-day vascular death | 90 days | Vascular death within 90 days after enrollment |
| 90-day all-cause death | 90 days | All-cause death within 90 days after enrollment |
| Discharge mRS | Through hospitalization, an average of 7 days | Modified Rankin scale at discharge |
| 90-day non-major bleeding | 90 days | Non-major bleeding within 90 days after enrollment |
Countries
China
Contacts
Primary ContactMin Lou, PhD
Outcome results
None listed